Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CFSAN priorities

This article was originally published in The Tan Sheet

Executive Summary

FDA's Center for Food Safety & Applied Nutrition is seeking comments from the public on what program priorities it should consider setting for 2007, the agency announces in a Federal Register notice published June 29. The input will be used to develop the center's 2007 workplan. A similar strategy was used to develop CFSAN's 2006 program priorities, which were published in May (1"The Tan Sheet" May 8, 2006, p. 10). To establish the 2006 goals, CFSAN asked, "Where do we do the most good for consumers and the overall public health?" the notice states. The 2007 plan will be divided into five sections: nutrition, dietary supplement safety, food defense, food safety and cosmetic safety...

You may also be interested in...



CFSAN Priorities: Industry & Consumer Groups Weigh In On NDIs And More

FDA should accept safety findings from outside expert panels when reviewing new dietary ingredient notifications, CHPA says in Aug. 25 comments on CFSAN priorities

CFSAN Shuffles 2006 Priorities To Work Within Budget; GMPs Ready By Fall?

FDA's Center for Food Safety & Applied Nutrition is scaling back its approach to program priorities for fiscal 2006 due to the "diminished budget" outlined in President Bush's 2007 spending proposal

‘A Forever Battle:’ Patent Reform, Launch Prices, And Where Lower Rx Price Advocates Will Go Next

Pharma’s opponents believe passage of the Inflation Reduction Act represents a momentum shift that will make it easier for politicians (even some Republicans) to take on the industry. They’ll need to count on that as they still have a long list of targets ahead on their lower-drug pricing agenda.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS099508

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel